Annual EBIT
-$24.73 M
-$2.21 M-9.83%
31 December 2023
Summary:
Lineage Cell Therapeutics annual earnings before interest & taxes is currently -$24.73 million, with the most recent change of -$2.21 million (-9.83%) on 31 December 2023. During the last 3 years, it has risen by +$1.71 million (+6.48%). LCTX annual EBIT is now -3433.29% below its all-time high of -$700.00 thousand, reached on 30 June 1992.LCTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$3.84 M
+$2.03 M+34.55%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly earnings before interest & taxes is currently -$3.84 million, with the most recent change of +$2.03 million (+34.55%) on 30 September 2024. Over the past year, it has increased by +$2.87 million (+42.73%). LCTX quarterly EBIT is now -321.48% below its all-time high of $1.73 million, reached on 31 December 2009.LCTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$22.73 M
+$2.87 M+11.19%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM earnings before interest & taxes is currently -$22.73 million, with the most recent change of +$2.87 million (+11.19%) on 30 September 2024. Over the past year, it has increased by +$2.28 million (+9.12%). LCTX TTM EBIT is now -22630.00% below its all-time high of -$100.00 thousand, reached on 31 March 1992.LCTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.8% | +42.7% | +9.1% |
| 3 y3 years | +6.5% | +43.9% | +15.4% |
| 5 y5 years | +39.7% | +54.4% | +46.2% |
LCTX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -9.8% | +49.7% | at high | +86.4% | -0.9% | +53.8% |
| 5 y | 5 years | -9.8% | +49.7% | at high | +86.4% | -0.9% | +53.8% |
| alltime | all time | -3433.3% | +62.4% | -321.5% | +86.4% | <-9999.0% | +70.5% |
Lineage Cell Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.84 M(-34.5%) | -$22.73 M(-11.2%) |
| June 2024 | - | -$5.87 M(-11.9%) | -$25.59 M(+3.4%) |
| Mar 2024 | - | -$6.66 M(+4.7%) | -$24.75 M(+0.1%) |
| Dec 2023 | -$24.73 M(+9.8%) | -$6.36 M(-5.1%) | -$24.73 M(-1.1%) |
| Sept 2023 | - | -$6.71 M(+33.5%) | -$25.01 M(+6.2%) |
| June 2023 | - | -$5.02 M(-24.4%) | -$23.56 M(+3.5%) |
| Mar 2023 | - | -$6.64 M(+0.0%) | -$22.77 M(+1.1%) |
| Dec 2022 | -$22.52 M(-54.2%) | -$6.64 M(+26.4%) | -$22.52 M(-49.0%) |
| Sept 2022 | - | -$5.25 M(+24.0%) | -$44.12 M(-3.5%) |
| June 2022 | - | -$4.23 M(-33.8%) | -$45.71 M(-5.9%) |
| Mar 2022 | - | -$6.40 M(-77.3%) | -$48.56 M(-1.3%) |
| Dec 2021 | -$49.21 M(+86.1%) | -$28.24 M(+312.7%) | -$49.21 M(+83.2%) |
| Sept 2021 | - | -$6.84 M(-3.3%) | -$26.86 M(+0.4%) |
| June 2021 | - | -$7.08 M(+0.4%) | -$26.74 M(+2.6%) |
| Mar 2021 | - | -$7.05 M(+19.9%) | -$26.06 M(-1.5%) |
| Dec 2020 | -$26.45 M(-32.0%) | -$5.88 M(-12.5%) | -$26.45 M(-3.6%) |
| Sept 2020 | - | -$6.72 M(+5.0%) | -$27.44 M(-5.8%) |
| June 2020 | - | -$6.40 M(-13.9%) | -$29.13 M(-13.2%) |
| Mar 2020 | - | -$7.44 M(+8.2%) | -$33.55 M(-13.7%) |
| Dec 2019 | -$38.88 M(-5.2%) | -$6.87 M(-18.4%) | -$38.88 M(-7.9%) |
| Sept 2019 | - | -$8.42 M(-22.2%) | -$42.22 M(-4.4%) |
| June 2019 | - | -$10.82 M(-15.2%) | -$44.15 M(+3.9%) |
| Mar 2019 | - | -$12.76 M(+24.9%) | -$42.48 M(+3.3%) |
| Dec 2018 | -$40.99 M(+0.8%) | -$10.21 M(-1.4%) | -$41.10 M(+1.6%) |
| Sept 2018 | - | -$10.36 M(+13.3%) | -$40.45 M(+2.1%) |
| June 2018 | - | -$9.14 M(-19.7%) | -$39.61 M(-2.9%) |
| Mar 2018 | - | -$11.39 M(+19.1%) | -$40.78 M(+0.3%) |
| Dec 2017 | -$40.66 M(-31.1%) | -$9.56 M(+0.5%) | -$40.66 M(-4.0%) |
| Sept 2017 | - | -$9.51 M(-7.8%) | -$42.35 M(-0.1%) |
| June 2017 | - | -$10.32 M(-8.4%) | -$42.39 M(-8.8%) |
| Mar 2017 | - | -$11.26 M(+0.1%) | -$46.47 M(-21.2%) |
| Dec 2016 | -$58.97 M(-10.4%) | -$11.25 M(+17.8%) | -$58.97 M(-15.0%) |
| Sept 2016 | - | -$9.55 M(-33.7%) | -$69.42 M(-9.8%) |
| June 2016 | - | -$14.40 M(-39.4%) | -$76.97 M(+1.2%) |
| Mar 2016 | - | -$23.76 M(+9.5%) | -$76.06 M(+15.6%) |
| Dec 2015 | -$65.81 M(+29.8%) | -$21.70 M(+26.9%) | -$65.80 M(+12.5%) |
| Sept 2015 | - | -$17.10 M(+26.7%) | -$58.50 M(+9.3%) |
| June 2015 | - | -$13.50 M(-0.0%) | -$53.54 M(+0.8%) |
| Mar 2015 | - | -$13.50 M(-6.2%) | -$53.10 M(+4.7%) |
| Dec 2014 | -$50.68 M(+31.5%) | -$14.40 M(+18.6%) | -$50.74 M(+5.3%) |
| Sept 2014 | - | -$12.14 M(-7.1%) | -$48.17 M(+4.2%) |
| June 2014 | - | -$13.06 M(+17.3%) | -$46.24 M(+12.0%) |
| Mar 2014 | - | -$11.14 M(-5.9%) | -$41.29 M(+7.2%) |
| Dec 2013 | -$38.53 M(+54.1%) | -$11.84 M(+16.0%) | -$38.53 M(+14.2%) |
| Sept 2013 | - | -$10.20 M(+25.7%) | -$33.76 M(+14.4%) |
| June 2013 | - | -$8.12 M(-3.1%) | -$29.50 M(+7.4%) |
| Mar 2013 | - | -$8.38 M(+18.7%) | -$27.46 M(+9.9%) |
| Dec 2012 | -$25.00 M(+33.8%) | -$7.06 M(+18.7%) | -$25.00 M(+6.8%) |
| Sept 2012 | - | -$5.95 M(-2.2%) | -$23.40 M(+7.9%) |
| June 2012 | - | -$6.08 M(+2.8%) | -$21.69 M(+5.3%) |
| Mar 2012 | - | -$5.92 M(+8.3%) | -$20.59 M(+10.1%) |
| Dec 2011 | -$18.69 M(+89.7%) | -$5.46 M(+29.0%) | -$18.70 M(+10.0%) |
| Sept 2011 | - | -$4.23 M(-15.0%) | -$16.99 M(+11.7%) |
| June 2011 | - | -$4.98 M(+23.7%) | -$15.22 M(+21.2%) |
| Mar 2011 | - | -$4.03 M(+7.2%) | -$12.55 M(+27.4%) |
| Dec 2010 | -$9.85 M(+179.9%) | -$3.75 M(+52.8%) | -$9.85 M(+125.8%) |
| Sept 2010 | - | -$2.46 M(+6.1%) | -$4.36 M(-9.8%) |
| June 2010 | - | -$2.32 M(+74.7%) | -$4.84 M(+33.2%) |
| Mar 2010 | - | -$1.33 M(-176.4%) | -$3.63 M(+12.9%) |
| Dec 2009 | -$3.52 M(+24.7%) | $1.73 M(-159.1%) | -$3.22 M(-45.6%) |
| Sept 2009 | - | -$2.93 M(+164.9%) | -$5.92 M(+51.8%) |
| June 2009 | - | -$1.11 M(+21.6%) | -$3.90 M(+4.2%) |
| Mar 2009 | - | -$911.30 K(-5.9%) | -$3.74 M(+15.6%) |
| Dec 2008 | -$2.82 M | -$968.00 K(+5.9%) | -$3.24 M(+28.1%) |
| Sept 2008 | - | -$913.90 K(-3.7%) | -$2.53 M(+42.8%) |
| June 2008 | - | -$949.30 K(+133.2%) | -$1.77 M(+58.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$407.10 K(+58.2%) | -$1.11 M(-8.9%) |
| Dec 2007 | -$1.22 M(-30.2%) | -$257.40 K(+65.3%) | -$1.22 M(-6.3%) |
| Sept 2007 | - | -$155.70 K(-47.0%) | -$1.31 M(-10.5%) |
| June 2007 | - | -$293.80 K(-43.0%) | -$1.46 M(-19.2%) |
| Mar 2007 | - | -$515.60 K(+51.6%) | -$1.81 M(+3.1%) |
| Dec 2006 | -$1.75 M(-13.2%) | -$340.10 K(+9.9%) | -$1.75 M(-6.5%) |
| Sept 2006 | - | -$309.50 K(-51.7%) | -$1.87 M(-4.8%) |
| June 2006 | - | -$641.20 K(+39.1%) | -$1.97 M(+12.2%) |
| Mar 2006 | - | -$461.10 K(-0.2%) | -$1.75 M(-13.1%) |
| Dec 2005 | -$2.02 M(+2.5%) | -$462.00 K(+14.4%) | -$2.02 M(-6.4%) |
| Sept 2005 | - | -$403.70 K(-5.5%) | -$2.16 M(-0.6%) |
| June 2005 | - | -$427.20 K(-41.1%) | -$2.17 M(-0.9%) |
| Mar 2005 | - | -$725.50 K(+21.0%) | -$2.19 M(+11.2%) |
| Dec 2004 | -$1.97 M(+16.5%) | -$599.40 K(+44.1%) | -$1.97 M(+12.9%) |
| Sept 2004 | - | -$416.00 K(-7.1%) | -$1.74 M(+3.5%) |
| June 2004 | - | -$447.90 K(-11.4%) | -$1.68 M(-2.6%) |
| Mar 2004 | - | -$505.50 K(+35.2%) | -$1.73 M(+2.4%) |
| Dec 2003 | -$1.69 M(-16.9%) | -$373.90 K(+4.6%) | -$1.69 M(-12.2%) |
| Sept 2003 | - | -$357.30 K(-27.5%) | -$1.92 M(+2.1%) |
| June 2003 | - | -$492.90 K(+5.8%) | -$1.89 M(-4.1%) |
| Mar 2003 | - | -$465.70 K(-23.5%) | -$1.97 M(-3.4%) |
| Dec 2002 | -$2.03 M(-41.8%) | -$609.00 K(+91.8%) | -$2.03 M(+9.5%) |
| Sept 2002 | - | -$317.60 K(-44.6%) | -$1.86 M(-24.9%) |
| June 2002 | - | -$573.30 K(+7.2%) | -$2.48 M(-18.2%) |
| Mar 2002 | - | -$534.70 K(+23.5%) | -$3.03 M(-12.3%) |
| Dec 2001 | -$3.49 M(-31.3%) | -$433.00 K(-53.6%) | -$3.45 M(-15.0%) |
| Sept 2001 | - | -$934.10 K(-17.0%) | -$4.06 M(-8.0%) |
| June 2001 | - | -$1.13 M(+17.4%) | -$4.41 M(-5.3%) |
| Mar 2001 | - | -$958.20 K(-7.9%) | -$4.66 M(-8.3%) |
| Dec 2000 | -$5.09 M(-11.6%) | -$1.04 M(-19.1%) | -$5.08 M(-7.6%) |
| Sept 2000 | - | -$1.29 M(-6.3%) | -$5.50 M(-16.9%) |
| June 2000 | - | -$1.37 M(-0.6%) | -$6.61 M(+4.3%) |
| Mar 2000 | - | -$1.38 M(-5.5%) | -$6.34 M(+10.1%) |
| Dec 1999 | -$5.76 M(+140.0%) | -$1.46 M(-39.2%) | -$5.76 M(+33.9%) |
| Sept 1999 | - | -$2.40 M(+118.2%) | -$4.30 M(+38.7%) |
| June 1999 | - | -$1.10 M(+37.5%) | -$3.10 M(+21.6%) |
| Mar 1999 | - | -$800.00 K(-33.3%) | -$2.55 M(-33.8%) |
| Dec 1998 | -$2.40 M(-34.2%) | - | - |
| Sept 1998 | - | -$1.20 M(+118.2%) | -$3.85 M(+2.7%) |
| June 1998 | - | -$550.00 K(-54.2%) | -$3.75 M(-14.8%) |
| June 1998 | -$3.65 M(+14.1%) | - | - |
| Mar 1998 | - | -$1.20 M(+33.3%) | -$4.40 M(+18.9%) |
| Dec 1997 | - | -$900.00 K(-18.2%) | -$3.70 M(+5.7%) |
| Sept 1997 | - | -$1.10 M(-8.3%) | -$3.50 M(+16.7%) |
| June 1997 | -$3.20 M(+60.0%) | -$1.20 M(+140.0%) | -$3.00 M(-23.1%) |
| Mar 1997 | - | -$500.00 K(-28.6%) | -$3.90 M(+18.2%) |
| Dec 1996 | - | -$700.00 K(+16.7%) | -$3.30 M(+32.0%) |
| Sept 1996 | - | -$600.00 K(-71.4%) | -$2.50 M(+8.7%) |
| June 1996 | -$2.00 M(-20.0%) | -$2.10 M(-2200.0%) | -$2.30 M(+130.0%) |
| Mar 1996 | - | $100.00 K(0.0%) | -$1.00 M(-37.5%) |
| Dec 1995 | - | $100.00 K(-125.0%) | -$1.60 M(-30.4%) |
| Sept 1995 | - | -$400.00 K(-50.0%) | -$2.30 M(0.0%) |
| June 1995 | -$2.50 M(+56.3%) | -$800.00 K(+60.0%) | -$2.30 M(+9.5%) |
| Mar 1995 | - | -$500.00 K(-16.7%) | -$2.10 M(+16.7%) |
| Dec 1994 | - | -$600.00 K(+50.0%) | -$1.80 M(+20.0%) |
| Sept 1994 | - | -$400.00 K(-33.3%) | -$1.50 M(+7.1%) |
| June 1994 | -$1.60 M(+23.1%) | -$600.00 K(+200.0%) | -$1.40 M(+16.7%) |
| Mar 1994 | - | -$200.00 K(-33.3%) | -$1.20 M(0.0%) |
| Dec 1993 | - | -$300.00 K(0.0%) | -$1.20 M(0.0%) |
| Sept 1993 | - | -$300.00 K(-25.0%) | -$1.20 M(+9.1%) |
| June 1993 | -$1.30 M(+85.7%) | -$400.00 K(+100.0%) | -$1.10 M(0.0%) |
| Mar 1993 | - | -$200.00 K(-33.3%) | -$1.10 M(+10.0%) |
| Dec 1992 | - | -$300.00 K(+50.0%) | -$1.00 M(+42.9%) |
| Sept 1992 | - | -$200.00 K(-50.0%) | -$700.00 K(+40.0%) |
| June 1992 | -$700.00 K | -$400.00 K(+300.0%) | -$500.00 K(+400.0%) |
| Mar 1992 | - | -$100.00 K | -$100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual EBIT year-on-year change?
- What is Lineage Cell Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly EBIT year-on-year change?
- What is Lineage Cell Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM EBIT year-on-year change?
What is Lineage Cell Therapeutics annual earnings before interest & taxes?
The current annual EBIT of LCTX is -$24.73 M
What is the all time high annual EBIT for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual earnings before interest & taxes is -$700.00 K
What is Lineage Cell Therapeutics annual EBIT year-on-year change?
Over the past year, LCTX annual earnings before interest & taxes has changed by -$2.21 M (-9.83%)
What is Lineage Cell Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of LCTX is -$3.84 M
What is the all time high quarterly EBIT for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly earnings before interest & taxes is $1.73 M
What is Lineage Cell Therapeutics quarterly EBIT year-on-year change?
Over the past year, LCTX quarterly earnings before interest & taxes has changed by +$2.87 M (+42.73%)
What is Lineage Cell Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of LCTX is -$22.73 M
What is the all time high TTM EBIT for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM earnings before interest & taxes is -$100.00 K
What is Lineage Cell Therapeutics TTM EBIT year-on-year change?
Over the past year, LCTX TTM earnings before interest & taxes has changed by +$2.28 M (+9.12%)